Launch of a New Service Utilizing Armed Antibody Technology
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「Research and development of Armed antibodies, including antibody-drug conjugates (ADCs) and radioisotope-labeled antibodies, is also active in the antibody therapeutics industry. We will leverage our strong antibody library and antibody technologies to provide new services in line with industry trends.」
The company has reconfirmed its policy of providing new services by leveraging technologies related to Armed antibodies, including ADCs and radioisotope-labeled antibodies. - FY2024First statedAnnual report
「Research and development of Armed antibodies, including antibody-drug conjugates (ADCs) and radioisotope-labeled antibodies, is also active in the antibody therapeutics industry. We will leverage our strong antibody library and antibody technologies to provide new services in line with industry trends.」
The company has disclosed for the first time its policy of providing new services by leveraging its technologies related to Armed antibodies, including ADCs and radioisotope-labeled antibodies.